2020 re­port cards con­tin­ue rolling in, with an­a­lysts de­tail­ing record-break­ing fundrais­ing for the UK

5 years ago
Financing

Bris­tol My­ers flags an­oth­er PhI­II suc­cess for one of their top block­buster prospects, clear­ing a path to the FDA

5 years ago
R&D

In­spec­tions: GAO calls on FDA to plan for back­log, re­view al­ter­na­tives

5 years ago
FDA+

Af­ter ran­corous threats and a clin­i­cal hold, Ap­plied Ther­a­peu­tics is set to re­sume pe­di­atric galac­tosemia study

5 years ago
FDA+

Con­cert crushed on PhII schiz­o­phre­nia flop; Am­gen's so­tora­sib gets BTD in Chi­na

5 years ago
News Briefing

Ar­cutis show­cas­es pos­i­tive PhI­II da­ta show­ing its top­i­cal cream scratched the sweet spot Ote­zla or steroids could­n't

5 years ago
R&D

Who are the young bio­phar­ma lead­ers shap­ing the in­dus­try? Nom­i­nate them for End­points' spe­cial re­port

5 years ago
Editor's note

The packed PD-(L)1 game just got an­oth­er play­er — a low-pro­file biosim­i­lars com­pa­ny look­ing to branch out with a ...

5 years ago
Deals

Ex­clu­sive: Johns Hop­kins pro­fes­sor and biotech col­leagues tout new tech to test Covid-19 vac­cine re­sponse

5 years ago
Coronavirus
Manufacturing

Khosla Ven­tures helps seed a next-gen re­gen­er­a­tive med­i­cines start­up boast­ing AI-based stem cell cul­tur­ing tech­nol­o­gy

5 years ago
Financing
Cell/Gene Tx

Ex­clu­sive: Third Rock­'s stealthy MO­MA Ther­a­peu­tics taps a long­time Mil­len­ni­um, Take­da vet as CEO

5 years ago
People

Hori­zon nabs an­oth­er rare dis­ease pipeline for the port­fo­lio in $3B buy­out. And As­traZeneca — a fu­ture ri­val — is ...

5 years ago
Deals

Biotech part­ner drops Glax­o­SmithK­line’s ad­ju­vant as it moves Covid-19 vac­cine in­to PhII/III, cit­ing ...

5 years ago
Deals
Coronavirus

Covid-19 roundup: Bay­er ex­pands deal with Cure­Vac to pro­duce shots; UK or­ders more Val­ne­va vac­cines

5 years ago
Coronavirus

In pur­suit of an HIV cure, Gilead jumps in­to a T cell-dri­ving vac­cine pro­gram with a $785M deal that trig­gers PhI

5 years ago
Deals

#WCLC21: Mer­ck pokes Bris­tol My­ers in the eye with Keytru­da da­ta show­ing safe­ty red flags in Yer­voy com­bo tri­al

5 years ago
Pharma

#WCLC21: As­traZeneca's EGFR in­hibitor Tagris­so cuts re­lapse, death risks in pa­tients with and with­out pri­or ...

5 years ago
Pharma

Josh Bilenker ends his brief role in an un­usu­al ex­per­i­ment at Eli Lil­ly, bow­ing out as head of their Loxo can­cer R&D ...

5 years ago
People

Cataba­sis Phar­ma­ceu­ti­cals snaps up HAE an­ti­body in buy­out; Glad­stone, UCSF sci­en­tist spear­head launch of neu­ro ...

5 years ago
News Briefing

Though still strug­gling, Bel­licum can re­sume tri­al on CAR-T hope­ful af­ter FDA lifts clin­i­cal hold

5 years ago
Cell/Gene Tx
FDA+

WCLC: As­traZeneca builds case for grow­ing ADC pipeline with dou­ble wins in ad­vanced lung can­cer

5 years ago
R&D

Gates Foun­da­tion backs gene ther­a­py pi­o­neer­s' sec­ond-gen Covid-19 vac­cine

5 years ago
Coronavirus

Michael Yang leads list of moves at Vi­a­Cyte, suc­ceed­ing Paul Laikind as CEO; Qasim Rizvi named CEO of Take­da part­ner ...

5 years ago
Peer Review

Is it time to stock up on wine? This pan­dem­ic could stretch out — and that has some ma­jor mar­ket im­pli­ca­tions

5 years ago
Bioregnum
Opinion
First page Previous page 749750751752753754755 Next page Last page
A service from the Financial Times